Fusion Pharm Stock Analysis
| FSPM Stock | USD 0.0001 0.00 0.00% |
200 Day MA 0.0001 | 50 Day MA 0.0001 | Beta 25.844 |
At this time, Fusion Pharm's Short and Long Term Debt is very stable compared to the past year. As of the 12th of February 2026, Short Term Debt is likely to grow to 1,451, while Long Term Debt is likely to drop 2,879. Fusion Pharm's financial risk is the risk to Fusion Pharm stockholders that is caused by an increase in debt.
As of the 12th of February 2026, Sale Purchase Of Stock is likely to grow to about 98.3 K, while Total Stockholder Equity is likely to drop (2.6 K). . Fusion Pharm is overvalued with Real Value of 8.4E-5 and Hype Value of 1.0E-4. The main objective of Fusion Pharm stock analysis is to determine its intrinsic value, which is an estimate of what Fusion Pharm is worth, separate from its market price. There are two main types of Fusion Pharm's stock analysis: fundamental analysis and technical analysis.
The Fusion Pharm stock is traded in the USA on OTCCE Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Fusion Pharm is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Fusion Stock trading window is adjusted to America/New York timezone.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. Fusion Stock Analysis Notes
The company recorded a loss per share of 0.15. Fusion Pharm last dividend was issued on the 27th of February 1998. The entity had 1:200 split on the 1st of March 2011. FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people. To learn more about Fusion Pharm call the company at 720-458-0686 or check out https://www.fusionpharminc.com.Fusion Pharm Investment Alerts
| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 67.01 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures |
Fusion Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.06 K.Fusion Profitablity
The company has Profit Margin (PM) of (1.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.24) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.24.Management Efficiency
Fusion Pharm has return on total asset (ROA) of (1.3769) % which means that it has lost $1.3769 on every $100 spent on assets. This is way below average. Fusion Pharm's management efficiency ratios could be used to measure how well Fusion Pharm manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Fusion Pharm's Other Assets are very stable compared to the past year. As of the 12th of February 2026, Intangible Assets is likely to grow to 102.64, while Total Assets are likely to drop 3,450.Effective leadership at Fusion Pharm drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Technical Drivers
Fusion Pharm technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Fusion Pharm Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Fusion Pharm price series with the more recent values given greater weights.
Fusion Pharm Outstanding Bonds
Fusion Pharm issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fusion Pharm uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fusion bonds can be classified according to their maturity, which is the date when Fusion Pharm has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Fusion Pharm Bond Ratings
Fusion Pharm financial ratings play a critical role in determining how much Fusion Pharm have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Fusion Pharm's borrowing costs.| Piotroski F Score | 3 | Frail | View |
| Beneish M Score | (410.50) | Unlikely Manipulator | View |
Fusion Pharm Debt to Cash Allocation
Many companies such as Fusion Pharm, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity.Fusion Pharm Total Assets Over Time
Fusion Pharm Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Fusion Pharm's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Fusion Pharm, which in turn will lower the firm's financial flexibility.Fusion Pharm Corporate Bonds Issued
Fusion Long Term Debt
Long Term Debt |
|
About Fusion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Fusion Pharm prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fusion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fusion Pharm. By using and applying Fusion Stock analysis, traders can create a robust methodology for identifying Fusion entry and exit points for their positions.
FusionPharm, Inc. develops, manufactures, and sells a line of cultivation containers under the PharmPod brand name in the United States. The company was founded in 1998 and is based in Commerce City, Colorado. Fusion Pharm operates under Pharmaceutical Retailers classification in the United States and is traded on OTC Exchange. It employs 4 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Fusion Pharm to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Funds Screener Now
Funds ScreenerFind actively-traded funds from around the world traded on over 30 global exchanges |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Fusion diversify its offerings? Factors like these will boost the valuation of Fusion Pharm. Market participants price Fusion higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fusion Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fusion Pharm's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.